title: Cell treatment after acute myocardial infarction prevents early decline in circulating IGF-1.
abstract: OBJECTIVE
  To examine the influence of intracoronary autologous bone marrow cell transplantation after acute myocardial infarction on circulating growth factors and their relationship to left ventricular function.
  
  
  METHODS
  Circulating insulin-like growth factor-1 (IGF-1), hepatocyte growth factor (HGF), stromal derived factor-1-alpha (SDF-1α), and transforming growth factor beta (TGF-β) were measured in patients randomized to cell treatment or control, in the ASTAMI study. Autologous cells were injected intracoronary on day 6; blood was sampled on days 5, 9, and at three months. Left ventricular ejection fraction was recorded by electrocardiogram-gated single photon emission computed tomography at six months.
  
  
  RESULTS
  Only change in IGF-1 from baseline to three months differed between groups (p = 0.024). A weak but significant correlation was found between left ventricular ejection fraction and the averaged IGF-1 concentrations of all patients (r = 0.24, p = 0.02). Patients with IGF-1 above or below median (102 ng/ml) had a left ventricular ejection fraction of 52.3% (±11.4) versus 46.4% (±12.2) respectively (p = 0.017).
  
  
  CONCLUSIONS
  Intracoronary bone marrow cell treatment after myocardial infarction attenuates a reduction in circulating IGF-1. IGF-1 levels over time were weakly, but significantly correlated to left ventricular ejection fraction.
authors.affiliation: Institute for Experimental Medical Research, Oslo University Hospital, Ullevål, University of Oslo, Oslo, Norway. h.k.grogaard@medisin.uio.no
authors.forename: Haakon K
authors.initials: HK
authors.lastname: Grøgaard
authors.forename: Ingebjørg
authors.initials: I
authors.lastname: Seljeflot
authors.forename: Ketil
authors.initials: K
authors.lastname: Lunde
authors.forename: Svein
authors.initials: S
authors.lastname: Solheim
authors.forename: Svend
authors.initials: S
authors.lastname: Aakhus
authors.forename: Kolbjørn
authors.initials: K
authors.lastname: Forfang
authors.forename: Harald
authors.initials: H
authors.lastname: Arnesen
authors.forename: Arnfinn
authors.initials: A
authors.lastname: Ilebekk
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D016026:Bone Marrow Transplantation / Q000379:methods*; D054377:Chemokine CXCL12 / Q000097:blood; D003326:Coronary Circulation; D005260:Female; D005500:Follow-Up Studies; D017228:Hepatocyte Growth Factor / Q000097:blood; D006801:Humans; D007269:Injections, Intra-Arterial; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000601:surgery*; D013318:Stroke Volume; D016212:Transforming Growth Factor beta / Q000097:blood; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D054377:Chemokine CXCL12; D016212:Transforming Growth Factor beta; D017228:Hepatocyte Growth Factor; D007334:Insulin-Like Growth Factor I